



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: 3000 Crystal Drive, Suite 1200, Arlington, VA 22202  
Washington, DC 20540  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAME INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/883,093	06/14/2001	Catherine Guenther	R-126	7936

890 11/14/2002

DELTAGEN, INC.  
1003 Hamilton Avenue  
Menlo Park, CA 94025

EXAMINER

WILSON, MICHAEL C

ART UNIT	PAPER NUMBER
----------	--------------

1632

DATE MAILED 11/14/2002

Please find below and or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office

Address ASSISTANT COMMISSIONER FOR PATENTS

Washington, D.C. 20231

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

EXAMINER

ART UNIT

PAPER

10

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

The reply filed on 11-7-02, paper number 9, is not fully responsive to the prior Office Action because of the following omission(s) or matter(s): a marked up version of the figure has not been provided. In addition, it would be more efficient to get a draftsman's review of the drawings before amending Figure 2A. To comply with the Sequence rules as required in the office action sent 10-2-02, paper number 7, applicants should insert a sentence describing Figure 2A as containing SEQ ID NO:1 into the description of Figure 2A-2B on page 8, line 13. After "hormone receptor genes," insert a description of Fig. 2A, e.g. - Figure 2A shows... (SEQ ID NO:1).--

See 37 CFR 1.111. Since the above-mentioned reply appears to be *bona fide*, applicant is given **ONE (1) MONTH or THIRTY (30) DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Patent and Trademark Office  
Washington, D.C. 20231